CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

Analysts anticipate Syndax Pharmaceuticals to report an earnings per share (EPS) of $-0.72. Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...

Shares of Corbus Pharmaceuticals slid after the company priced its public offering at $13 a share. The stock declined 24% to $12.49 on Friday. Shares are down 22% in the past 12 months.

Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the stock in question is rocketing higher ...

Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...

and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip Small Stocks, Big Money ™ show, a sponsored program on Bloomberg TV ...